Patents Represented by Attorney, Agent or Law Firm Mary K. Hehman
-
Patent number: 8324160Abstract: The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating metabolic disorders such as diabetes and obesity using such nucleic acids, polypeptides, or pharmaceutical compositions.Type: GrantFiled: June 16, 2010Date of Patent: December 4, 2012Assignee: Amgen Inc.Inventors: Yang Li, Xinle Wu, Zhulun Wang
-
Patent number: 8071538Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: GrantFiled: August 23, 2010Date of Patent: December 6, 2011Inventors: Hq Han, Hosung Min, Thomas C. Boone
-
Patent number: 8034771Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.Type: GrantFiled: September 10, 2007Date of Patent: October 11, 2011Assignee: Amgen Inc.Inventors: John E. Sims, Blair R. Renshaw, Christopher Gabel, Jennifer E. Towne, Randal R. Ketchem
-
Patent number: 7964193Abstract: Antibodies directed to the antigen IL-1? and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1?. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: GrantFiled: June 19, 2009Date of Patent: June 21, 2011Assignee: Amgen Fremont Inc.Inventors: Larry Green, Raffaella Faggioni, Orit Foord, Scott L. Klakamp, Giorgio Senaldi, Amy K. Schneider
-
Patent number: 7867481Abstract: The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.Type: GrantFiled: December 22, 2004Date of Patent: January 11, 2011Inventors: Jonathan Kay, Dorothy McCabe, Richard Newmark, Marco A. Coccia
-
Patent number: 7767793Abstract: DNA encoding SIGIRR polypeptides and methods for using the encoded polypeptides are disclosed.Type: GrantFiled: October 30, 2007Date of Patent: August 3, 2010Inventor: John Ernest Sims
-
Patent number: 7659375Abstract: The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in cellular and immune reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, and kits comprising these reagents.Type: GrantFiled: June 25, 2007Date of Patent: February 9, 2010Assignee: Immunex CorporationInventors: John E Sims, Dirk E Smith
-
Patent number: 7566772Abstract: Antibodies directed to the antigen IL-1? and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1?. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: GrantFiled: January 19, 2006Date of Patent: July 28, 2009Assignee: Amgen Fremont Inc.Inventors: Larry Green, Raffaella Faggioni, Orit Foord, Scott L. Klakamp, Giorgio Senaldi, Amy K. Schneider
-
Patent number: 6346655Abstract: The present invention discloses trichothecene-resistant transgenic plants, plant tissues, plant seeds, and plant cells comprising a heterologous polynucleotide encoding a gene product having tricothecene resistance activity that thereby confers trichothecene resistance to the transgenic plants, plant tissues, plant seeds, and plant cells. Trichothecene resistance activity, as used herein, refers to an activity that reduces or inhibits the phytotoxicity of a trichothecene, particularly to a fungus and/or plant.Type: GrantFiled: March 29, 2000Date of Patent: February 12, 2002Assignee: Syngenta Participations AGInventors: Thomas M. Hohn, Cheryl Peters, John Salmeron
-
Patent number: 6188003Abstract: An inbred sweet corn line, designated R762, the plants and seeds of inbred sweet corn line R762, methods for producing a maize plant produced by crossing the inbred sweet corn line R762 with itself or with another maize plant, and hybrid maize seeds and plants produced by crossing the inbred sweet corn line R762 with another maize line or plant.Type: GrantFiled: May 24, 1999Date of Patent: February 13, 2001Assignee: Novartis AGInventors: Douglas C. Plaisted, Stephen L. Grier, Wesley Houghton
-
Patent number: 6057492Abstract: Plant transformation vectors comprising a polynucleotide effective to render resisitance or tolerance to infection by a tospovirus, and a microbiological process for making virus tolerant or resistant plants are provided herein.Type: GrantFiled: September 18, 1997Date of Patent: May 2, 2000Assignee: Novartis ABInventor: Petrus Theodorus de Haan
-
Patent number: 5981844Abstract: Novel plant proteins (SAFPs) which synergize the activity of antifungal antibiotics are identified. SAFPs are demonstrated to synergize antifungal antibiotics, such as nikkomycins, polyoxins and amphotericins. SAFPs alone also display antifungal activity against several species of fungi, including strains of Candida, Trichoderma, Neurospora and strains of the plant pathogens Fusarium, Rhizoctonia and Chaetomium. Synergistic antifungal compositions containing SAFP and antifungal antibiotics are provided. In particular, synergistic compositions of corn-SAFP (zeamatin), sorghum-SAFP (sormatin) or oat-SAFP (avematin) and nikkomycin are found to be effective as antifungal compositions, especially against the opportunistic human pathogen Candida albicans. Method for employing SAFPs and synergistic compositions containing them for the inhibition of fungi are provided. In addition, a method for purifying SAFP from grain meal is provided.Type: GrantFiled: December 19, 1997Date of Patent: November 9, 1999Assignees: Novartis Finance Corporation, University Research CorporationInventors: Walden K. Roberts, Claude P. Selitrennikoff, Bridget E. Laue, Sharon L. Potter